Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study

BackgroundWe sought to report the effectiveness of infliximab and adalimumab over the first 3 years of treatment and to define the factors that predict anti-TNF treatment failure and the strategies that prevent or mitigate loss of response.MethodsPersonalised Anti-TNF therapy in Crohn's disease (PANTS) is a UK-wide, multicentre, prospective observational cohort study reporting the rates of effectiveness of infliximab and adalimumab in anti-TNF-naive patients with active luminal Crohn's disease aged 6 years and older. At the end of the first year, sites were invited to enrol participants still receiving study drug into the 2-year PANTS-extension study. We estimated rates of remission across the whole cohort at…

• P
  Pfizer
• A
  AbbVie
• C
  Celltrion
• NI
  National Institute for Health and Care Research
• CA
  Crohn's and Colitis UK
• GU
  Guts UK
• MS
  Merck Sharp and Dohme
• MR
  Medical Research Council

  Awards: MC_PC_MR/S025952/1, MC_UU_00036/1, MC_UU_00008/7
• NE
  NIHR Exeter Clinical Research Facility